Table 1 Baseline characteristics
Unique patients (n = 3754) | |||
|---|---|---|---|
Age (years), mean (SD) | 76.7 (8.3) | ||
Male, n (%) | 1764 (47.0) | ||
Rule alerts, n (%) | Day one | Â | Day seven |
Total | 7907 (100) | 5261 (100) | |
Total number of top 20 rule alerts, n (%) | 7156 (90.5) | 4757 (90.4) | |
Top 20 of rule alerts, n (%)* | |||
Potassium levels | 2170 (30.3) | Â | 1418 (30.0) |
MDRD required | 942 (13.2) | 885 (18.6) | |
Anticoagulation therapy and INR | 587 (8.2) | 384 (8.1) | |
Renal dysfunction + Levetiracetam | 428 (6.0) | 185 (3.9) | |
Long use antibiotic therapy | 366 (5.1) | 322 (6.8) | |
Renal dysfunction + Tazocin/Piperacillin | 346 (4.8) | 149 (3.1) | |
Renal dysfunction + Cefazolin | 266 (3.7) | 211 (4.4) | |
Potassium levels + Digoxin | 247 (3.5) | 189 (4.0) | |
Opioids without laxative agents | 225 (3.1) | 201 (4.2) | |
Renal dysfunction + Barnidipine | 195 (2.7) | 95 (2.0) | |
Renal dysfunction + Valaciclovir | 175 (2.4) |  | 71 (1.5) |
Renal dysfunction + Benzylpenicillin | 166 (2.3) | 56 (1.2) | |
Renal dysfunction + Amoxicillin | 147 (2.0) | 53 (1.1) | |
Intravenous to oral switch- Metronidazole | 145 (2.0) | 136 (2.9) | |
Renal dysfunction + Sucralfate | 141 (2.0) | 47 (1.0) | |
Renal dysfunction + Pramipexole | 139 (1.9) | 64 (1.3) | |
Intravenous to oral switch -Flucloxacillin | 129 (1.8) | 97 (2.0) | |
Renal dysfunction + Meropenem | 97 (1.4) | 38 (0.8) | |
Renal dysfunction + amoxicillin/clavulanic acid | 96 (1.3) | 75 (1.6) | |
Renal dysfunction + Tranexamic acid | 84 (1.2) | 71 (1.5) | |